Noninvasive tools to assess liver disease
Noninvasive tools to assess liver disease
复制标题
DOI：
10.1097/mog.0b013e328343e9a3
复制
发表时间：
2011-05-01
影响因子：
2.5
通讯作者：
Patel, Keyur
中科院分区：
文献类型：
--
作者：
Clark, Paul J.;Patel, Keyur
目的reviewTo提高对纤维化的非侵入性评估的最新进展及其对一系列慢性肝病的潜在临床应用的理解。最近的发现许多非侵入性测试已经从慢性丙型肝炎病毒（HCV）感染的主要验证发展到各种原因的慢性肝病的临床管理算法。最近的研究考虑顺序或组合使用这些技术，并比较血清和基于成像的非侵入性技术的性能，以识别具有显著纤维化的患者，或晚期疾病临床后遗症风险最高的患者。在慢性丙型肝炎中开发的方法现在已应用于不同的慢性肝病，包括非酒精性脂肪性肝病，酒精性肝病，HIV/HCV合并感染和原发性胆汁性肝硬化。一些新的管理算法已经开发，以促进非侵入性技术融入临床practice.SummaryNoninvasive工具，以评估肝脏疾病继续发展。已经开发了新的成像技术。现有的生物标志物和成像模式已被更好地整合到临床实践算法中，并应用于不同的慢性肝病。非侵入性技术可能会继续完善，并在未来慢性肝病患者的管理中发挥重要作用。
Purpose of reviewTo improve understanding of recent developments in the noninvasive assessment of fibrosis and their potential clinical application to a range of chronic liver diseases.Recent findingsMany noninvasive tests have evolved from their primary validation in chronic hepatitis C virus (HCV) infection to integration into clinical management algorithms for chronic liver disease of varying cause. Recent studies consider the use of these techniques in sequence or in combination, and compare the performance of serum and imaging-based noninvasive techniques to identify patients with significant fibrosis, or those at most risk of clinical sequelae from advanced-stage disease. Methods developed in chronic hepatitis C have now been applied in different chronic liver diseases, including nonalcoholic fatty liver disease, alcoholic liver disease, HIV/HCV co-infection and primary biliary cirrhosis. A number of new management algorithms have been developed to facilitate the integration of noninvasive techniques into clinical practice.SummaryNoninvasive tools to assess liver diseases continue to evolve. New imaging technologies have been developed. Existing biomarkers and imaging modalities have been better integrated into clinical practice algorithms, and applied to different chronic liver diseases. Noninvasive techniques will likely continue to be refined and play an important role in the future management of patients with chronic liver disease.